‘Sleep Attacks’ or ‘Unintended Sleep Episodes’ Occur with Dopamine Agonists: Is This a Class Effect?

Author： Chaudhuri K.R.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.7, 2002-01, pp. : 473-483

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sleep Attacks and Dopamine Agonists for Parkinson’s Disease: What is Currently Known?

By Zesiewicz T.A.   Hauser R.A.  

CNS Drugs, Vol. 17, Iss. 8, 2003-01 ,pp. : 593-600

Adis International

Access to resources Recommend Favorite

Hepatotoxicity with Thiazolidinediones: Is it a Class Effect?

By Scheen A.J.  

Drug Safety, Vol. 24, Iss. 12, 2001-01 ,pp. : 873-888

Adis International

Access to resources Recommend Favorite

NSAIDs and the risk of CV events: is there a class effect?

By  

Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease?

By Le W-D.   Jankovic J.  

Drugs & Aging, Vol. 18, Iss. 6, 2001-06 ,pp. : 389-396

Adis International

Access to resources Recommend Favorite

Dopamine agonists cost effective for cotherapy of Parkinson's disease?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 332, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite